The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease
Open accessAbstract
UNLABELLED: Previous studies examining the relationship between hepatic iron deposition and histological severity in nonalcoholic fatty liver disease (NAFLD) have been inconclusive. The goal of this study was to examine the relationship between hepatic iron deposition and liver histology in 849 patients enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatic iron staining was performed in a central laboratory, and the stains were scored for grade and cellular and parenchymal localization by a central pathology committee; the relationship between the grade and pattern of iron deposition and the clinical, laboratory, and histological variables was examined with univariate and multivariate analyses. Stainable hepatic iron was present in 293 of 849 patients (34.5%) in one of three histological patterns: a hepatocellular (HC) pattern [63/849 (7.4%)], a reticuloendothelial system (RES) cell pattern [91/849 (10.7%)], or a mixed RES/HC pattern [139/849 (16.4%)]. Patients with the RES iron-staining pattern were more likely to have advanced fibrosis compared to those with those with HC iron (P = 0.01). Patients with RES iron were also more likely to have advanced histological features such as fibrosis (P = 0.049), portal inflammation (P = 0.002), HC ballooning (P = 0.006), and definite nonalcoholic steatohepatitis (P = 0.007) compared to those with patients with HC or mixed iron patterns. The presence of RES iron (odds ratio = 1.60, 95% confidence interval = 1.10-2.33, P = 0.015) was independently associated with advanced hepatic fibrosis on multiple regression analysis after adjustments for age, gender, diabetes status, and body mass index. CONCLUSION: The presence and pattern of hepatic iron deposition are associated with distinct histological features in patients with NAFLD and may have implications for pathophysiology and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 4×
“2-4 (20 ) 213 (38) 22 (35) 44 (48) 53 (38)”
InfluentialSzczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
Interleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 4×
“AST (U/L) 45 (32-68) 40 (31-56) 58 (39-77) 45 (33-63) 0.”
InfluentialGeorge, D. K., Goldwurm, S., Macdonald, G. A., Cowley, L. L., Walker, N. I., Ward, P. J., Jazwinska, E. C., & Powell, L. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70482-2 · Cited by 659
A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression
Wang, R.-H., Li, C., Xu, X., Zheng, Y., Xiao, C., Zerfas, P., Cooperman, S., Eckhaus, M., Rouault, T., Mishra, L., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.10.010 · Cited by 614
Regulation of hepcidin transcription by interleukin-1 and interleukin-6
Lee, P., Peng, H., Gelbart, T., Wang, L., & Beutler, E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409808102 · Cited by 543
Bekri, S., Gual, P., Anty, R., Luciani, N., Dahman, M., Ramesh, B., Iannelli, A., Staccini–Myx, A., Casanova, D., Ben Amor, I., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.007 · Cited by 496
Cited by
Kowdley, K. V., Belt, P., Wilson, L. A., Yeh, M. M., Neuschwander–Tetri, B. A., Chalasani, N., Sanyal, A. J., & Nelson, J. E. (2012) · Hepatology · doi:10.1002/hep.24706 · Cited by 543
Self-citationTsurusaki, S., Tsuchiya, Y., Koumura, T., Nakasone, M., Sakamoto, T., Matsuoka, M., Imai, H., Yuet-Yin Kok, C., Okochi, H., Nakano, H., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1678-y · Cited by 529
Oxidative Stress in Liver Pathophysiology and Disease
Allameh, A., Niayesh-Mehr, R., Aliarab, A., Sebastiani, G., & Pantopoulos, K. (2023) · Antioxidants · doi:10.3390/antiox12091653 · Cited by 514
Wong, V. W.-S., Chu, W. C.-W., Wong, G. L.-H., Chan, R. S.-M., Chim, A. M.-L., Ong, A., Yeung, D. K.-W., Yiu, K. K.-L., Chu, S. H.-T., Woo, J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300342 · Cited by 491
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15539 · Cited by 486
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Brown, G. T., & Kleiner, D. E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.008 · Cited by 363
Self-citationIron in fatty liver and in the metabolic syndrome: A promising therapeutic target
Dongiovanni, P., Fracanzani, A. L., Fargion, S., & Valenti, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.008 · Cited by 362
Ferroptosis in Liver Diseases: An Overview
Capelletti, M. M., Manceau, H., Puy, H., & Peoc’h, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144908 · Cited by 361
Pathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 346
Self-citationPathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 335
Self-citationWei, J. L., Leung, J. C.-F., Loong, T. C.-W., Wong, G. L.-H., Yeung, D. K.-W., Chan, R. S.-M., Chan, H. L.-Y., Chim, A. M.-L., Woo, J., Chu, W. C.-W., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.235 · Cited by 318
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 293
Roth, C. L., Elfers, C. T., Figlewicz, D. P., Melhorn, S. J., Morton, G. J., Hoofnagle, A., Yeh, M. M., Nelson, J. E., & Kowdley, K. V. (2012) · Hepatology · doi:10.1002/hep.24737 · Cited by 290
Self-citationMacrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism
Lefere, S., & Tacke, F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.004 · Cited by 278
Iron and liver fibrosis: Mechanistic and clinical aspects
Mehta, K. J., Farnaud, S. J., & Sharp, P. A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i5.521 · Cited by 269
Borrelli, A., Bonelli, P., Tuccillo, F. M., Goldfine, I. D., Evans, J. L., Buonaguro, F. M., & Mancini, A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.009 · Cited by 266
Lytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225
“Moreover, iron accumulation from metabolic dysfunction, aggravates NASH, such as in liver siderosis observed in some NASH patients [105], and primary hemochromatosis exacerbates NASH [106], while iron removal ameliorates liver damage and serum ALT [107].”
BackgroundAberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis
Gao, H., Jin, Z., Bandyopadhyay, G., Wang, G., Zhang, D., Rocha, K. C. E., Liu, X., Zhao, H., Kisseleva, T., Brenner, D. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.006 · Cited by 224
Hepatic macrophages: Key players in the development and progression of liver fibrosis
Cheng, D., Chai, J., Wang, H., Fu, L., Peng, S., & Ni, X. (2021) · Liver International · doi:10.1111/liv.14940 · Cited by 188
Iron and the pathophysiology of diabetes
Harrison, A. V., Lorenzo, F. R., & McClain, D. A. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022522-102832 · Cited by 161
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
Genetics, genetic testing, and management of hemochromatosis: 15 years since hepcidin
Pietrangelo, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.045 · Cited by 136
Lu, S., Mott, J. L., & Harrison-Findik, D. D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.648212 · Cited by 24
Liang, Y., Luo, S., Bell, S., Mo, J. M. Y., He, B., Zhou, Y., Bai, X., & Au Yeung, S. L. (2024) · BMC Medicine · doi:10.1186/s12916-024-03486-w · Cited by 8
Shteyer, E., Nitzan, I., Godfarb, A., Hemed, N., & Revel‐Vilk, S. (2015) · Vox Sanguinis · doi:10.1111/vox.12223 · Cited by 3
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2025) · Diabetes mellitus · doi:10.14341/dm13340 · Cited by 1
Metadata
- Authors
- Nelson, J. E., Wilson, L., Brunt, E. M., Yeh, M. M., Kleiner, D. E., Unalp-Arida, A., & Kowdley, K. V.
- Venue
- Hepatology
- Published
- 2010-11-29
- Volume
- 53
- Issue
- 2
- Pages
- 448-457
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2006999442
- Cited by
- 356
- References
- 51
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.